BiCNU

Bristol-Myers Squibb | BiCNU (Medication)


Desc:

BiCNU/carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:brain tumors - glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors; multiple myeloma - in combination with prednisone; Hodgkin's Disease; Non-Hodgkin's lymphomas. ...

Side Effect:

Nausea and vomiting after IV administration of BiCNU (carmustine) are noted frequently. A reversible type of hepatic toxicity, manifested by increased transaminase, alkaline phosphatase and bilirubin levels, has been reported in a small percentage of patients receiving BiCNU.

Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. ...

Precaution:

You should not receive this medication if you are allergic to carmustine or if you have any other allergies.

Inform your doctor if you have any of these other conditions:bone marrow suppression; liver disease; kidney disease; or a history of lung or breathing problems.

During pregnancy and breastfeeding is not recommended to use this medicine without your doctor's advice. ...